Завершено
Фаза III
Здоровые добровольцы
Россия
Recombinant two-component COVID-19 vaccine (CHO cell); Placebo · Jiangsu Rec-Biotechnology Co., Ltd.
A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older